Understanding the Investigation of Longboard Pharmaceuticals
Ademi LLP has launched an investigation into Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) regarding a recent transaction with Lundbeck. This inquiry is focused on potential breaches of fiduciary duty and various other legal violations that may affect Longboard shareholders.
Details of the Transaction
In the ongoing transaction, Longboard shareholders are being offered only $60.00 per share in a tender offer, leading to an estimated equity value of approximately $2.6 billion for the company. The details of the transaction raise significant concerns, particularly regarding how it affects shareholder rights and future opportunities for alternative bids.
Concerns Over Competing Transactions
This transaction agreement appears to impose unreasonable limitations on potential competing offers for Longboard Pharmaceuticals. Specifically, it includes a substantial penalty should Longboard consider and accept any competing bid. Such restrictions could significantly hinder shareholder value and the overall market dynamics regarding this transaction.
Benefits for Insiders
Another point of concern is the substantial benefits that Longboard's insiders stand to gain as part of the change of control arrangements during this transition. Such arrangements may indicate potential conflicts of interest, highlighting the need for thorough scrutiny by the board of directors and legal entities. Shareholders deserve to know that their interests are being prioritized in all decisions made by the company's management.
Fiduciary Duties of the Board
Ademi LLP's investigation aims to determine whether the Longboard board of directors is adhering to their fiduciary responsibilities towards all shareholders. This includes ensuring that fair value is being provided to shareholders in addition to examining if proper due diligence was conducted during the negotiation phase of the transaction.
Contact for More Information
If you own common stock of Longboard Pharmaceuticals and are seeking additional information regarding this investigation, you are encouraged to reach out to Guri Ademi directly at 866-264-3995. This inquiry is being conducted at no cost or obligation to you, emphasizing the commitment to safeguarding shareholder rights.
Specialization in Shareholder Litigation
Ademi LLP specializes in shareholder litigation that spans various critical areas, including buyouts, mergers, and the safeguarding of individual shareholder rights across the nation. The firm is dedicated to providing equitable representation for shareholders, ensuring that their rights are protected in all facets of corporate transactions.
Frequently Asked Questions
What is the current situation with Longboard Pharmaceuticals?
The firm is currently investigating potential breaches of fiduciary duty related to Longboard's transaction with Lundbeck.
How is the value of Longboard Pharmaceuticals being calculated?
The company is valued at approximately $2.6 billion with a tender offer set at $60.00 per share.
What are the roles of the insiders in the transaction?
Insiders are expected to receive substantial benefits during the transition, which raises concerns about potential conflicts of interest.
How can shareholders get involved in the investigation?
Shareholders can learn more and join the investigation by contacting Guri Ademi at 866-264-3995 for more details.
What types of cases does Ademi LLP handle?
The firm specializes in litigation that involves buyouts, mergers, and individual shareholder rights throughout the United States.
